An Observational Study of Ocrelizumab Treated Patients with Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (VERISMO Study)

31/07/2019
14/03/2024
EU PAS number:
EUPAS30752
Study
Ongoing
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol BA39731 OCREVUS v1_Redacted_final

English (1.95 MB - PDF) View document
Updated protocol

Prot BA39731 ocrelizumab v3, Published Output-1_Redacted

First published: 22/02/2024
English (1.42 MB - PDF) View document
Study results
Study report
Other information